Skip to main navigation Skip to search Skip to main content

Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

  • D. E. Reece
  • , C. Bredeson
  • , W. S. Pérez
  • , S. Jagannath
  • , M. J. Zhang
  • , K. K. Ballen
  • , G. J. Elfenbein
  • , C. O. Freytes
  • , R. P. Gale
  • , M. A. Gertz
  • , J. Gibson
  • , S. A. Giralt
  • , A. Keating
  • , R. A. Kyle
  • , D. Maharaj
  • , D. Marcellus
  • , P. L. McCarthy
  • , G. A. Milone
  • , S. D. Nimer
  • , S. Pavlovsky
  • L. B. To, D. J. Weisdorf, P. H. Wiernik, J. R. Wingard, D. H. Vesole
  • Princess Margaret Hospital
  • Medical College of Wisconsin
  • Saint Vincent Catholic Medical Centers
  • University of Massachusetts Medical School
  • Roger Williams Hospital
  • University of Texas Health Science Center at San Antonio
  • Ctr. for Advanced Stud. in Leukemia
  • Mayo Clinic Rochester, MN
  • Royal Prince Alfred Hospital
  • University of Texas MD Anderson Cancer Center
  • Bethesda Health City
  • Hamilton Health Sciences
  • Roswell Park Cancer Institute
  • Fundaleu
  • Memorial Sloan-Kettering Cancer Center
  • Hanson Institute
  • University of Minnesota Twin Cities
  • New York Medical College
  • University of Florida

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

Original languageEnglish
Pages (from-to)1135-1143
Number of pages9
JournalBone Marrow Transplantation
Volume32
Issue number12
DOIs
StatePublished - Dec 2003

Keywords

  • Autologous transplantation
  • Multiple myeloma
  • Older patients

Fingerprint

Dive into the research topics of 'Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age'. Together they form a unique fingerprint.

Cite this